蔡璐璐 - 电子科技大学

个人简介

2018/9-至今，美国加州大学洛杉矶分校（UCLA）,生物工程系,访问助理项目科学家，合作导师，顾臻教授；2017/5-2018/8，美国北卡罗来纳大学教堂山分校/北卡罗来纳州立大学,生物医学工程系,博士后助理，合作导师，顾臻教授；2016/5-2017/5，电子科技大学医学院(四川省人民医院),药学部,副研究员；2014/6-2017/5，四川大学,生物治疗国家重点实验室，在职博士后，导师：魏于全院士；2014/5-2015/5，日本京都药科大学,药剂学分野，中国卫生部-日本医学协会第34期“笹川医学奖学金”进修生，导师：山本昌教授2012/7-2016/4，四川省人民医院，药学部，助理研究员；2007.09-2012.07四川大学生物治疗国家重点实验室硕博连读药学博士学术经历：蔡璐璐，副研究员，博士，硕士研究生导师，四川省人社厅学术和技术带头人后备人,主持国家自然科学青年基金及四川省杰出青年科学基金。近十年来致力于肿瘤治疗领域新药新制剂的研究与开发。先后承担了国家自然科学青年基金，国家博士后基金面上项目，四川省杰出青年科学基金，四川省科技厅科技支撑项目，四川省卫生计生委应用基础项目，四川省中医药管理局青年项目等各级科研项目，曾参与863国家级科研项目、科技部“十一五”药物重大专项资助和四川省科技厅科技攻关重点项目等各级项目。主要研究成果发表在NanoResearch(IF=7.994),Nanoscale(IF=7.233)，DrugDiscoveryToday(IF=6.369)，JBiomedNanotechnol(IF=5.068),JMaterChemB(IF=4.776)，IntJNanomed(IF=4.370)及IntJPharm(IF=3.862)等SCI杂志上30余篇。论文被NatRevMicrobiol,PharmacolRev，Nanotoxicology，JControlRelease，Biomaterials，CancerTreatRev等国际期刊引用600余次，H因子13(GoogleScholar数据)。同时受邀担任NanoResearch,Nanoscale,Biomaterials,IntJPharm,IntJNanomed等国际杂志的审稿人。已申请纳米药物方向中国发明专利7项。个人简介：主要涉及肿瘤治疗领域新药新制剂的研究与开发。主持国家自然基金青年基金1项；中国博士后面上基金1项；四川省杰出青年科技基金1项；四川省科技厅科技支撑计划项目1项;四川省卫生计生委应用基础项目1项；四川省中医药管理局青年项目一项；四川省人社厅留学择优资助项目1项；与企业合作横向项目1项。硕士招生专业 105500药物研究与转化 02方向：药物研究与转化

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Advancesinglycosylation-mediatedcancer-targeteddrugdelivery.DrugDiscoveryToday,2018,23(5),1126-1138.2.Tumormicroenvironment-responsivehyaluronate-calciumcarbonatehybridnanoparticleenableseffectivechemotherapyforprimaryandadvancedosteosarcomas.NanoResearch,2018,11(9):4806–4822.3.Synthesis,mechanicalinvestigation,andapplicationofnitrogenandphosphorusco-dopedcarbondotswithahighlyphotoluminescentquantumyield.NanoResearch,2018,11(7):3691–3701.4.Multidimensionaltheranosticsfortumorfluorescenceimaging,photoacousticimagingandphotothermaltreatmentbasedonmanganesedopedcarbondots.JBiomedicalNanotechnology,2018,14(9),1590-1600.5.Gambogicacid-loadedpolymericmicellesforimprovedtherapeuticeffectinbreastcancer.JBiomedicalNanotechnology,2018,14(10),1695-1704.6.Synthesisofhighlyfluorescentyellow‐greenN‐dopedcarbonnanoringsforpHvariationdetectionandbioimaging.Particle&ParticleSystemsCharacterization,2018:1800276.7.Theapplicationofnaturalproductsincancertherapybytargetingapoptosispathways.Currentdrugmetabolism,2018,19(9),739-749.8.Efficientcocktailchemotherapybyco-deliveryofhydrogensul?de-releasingaspirinprodrugandpaclitaxelviasinglenanoparticles.RSCAdvances,2017,7,13458–13466.9.HighlyfluorescentZn-dopedcarbondotsasFentonreaction-basedbio-sensors:anintegrativeexperimental–theoreticalconsideration.Nanoscale,2016,8(41):17919-17927.10.Heteroatom-dopedcarbondots:synthesis,characterization,properties,photoluminescencemechanismandbiologicalapplications.JournalofMaterialsChemistryB,2016,4(45):7204-7219.11.Comparativestudyof(Asp)7-CHOLmodifiedliposomepreparedusingpre-insertionandpost-insertionmethodsforbonetargetinginvivo.JournalofDrugTargeting,2016,25:149–155.12.Anintegratedinsilicomethodtodiscovernovelrock1inhibitors:multi-complex-basedpharmacophore,moleculardynamicssimulationandhybridprotocolvirtualscreening.Combinatorialchemistry&highthroughputscreening,2016,19:36-50.13.Computationalanalysisofspiro-oxindoleinhibitorsoftheMDM2-p53interaction:insightsandselectionofnovelinhibitors.JournalofBiomolecularStructureandDynamics,2016:34(2),341-351.14.Novelnaproxen-peptide-conjugatedamphiphilicdendrimerself-assemblymicellesfortargetingdrugdeliverytoosteosarcomacells.RSCAdvances.2016,6:60327-60335.15.Barbigerone-in-hydroxypropyl-β-cyclodextrin-liposomalnanoparticle:preparation,characterizationandanti-canceractivities.JournalofInclusionPhenomenaandMacrocyclicChemistry,2015,82(3-4):505-514.16.Synthesisandinvitroevaluationof4-substitutedfurano[3,2-c]tetrahydroquinolinesaspotentialanti-canceragents.Journalofenzymeinhibitionandmedicinalchemistry,2015:1-6.17.Improvingaqueoussolubilityandantitumoreffectsbynano-sizedgambogicacid-mPEG2000micelles.IntJNanomedicine.2014,9:1-13.18.PeptideligandandPEG-mediatedlong-circulatingliposometargetedtoFGFRover-expressingtumorinvivo.IntJNanomedicine.2012,7:4499-510.19.Preparationofthethienopyridinederivativesloadedliposomesandstudyontheeffectofcompound-lipidinteractiononreleasebehavior.DrugDeliv.2012,19(5):247–254.20.Asystemicadministrationofliposomalcurcumininhibitsradiationpneumonitisandsensitizeslungcarcinomatoradiation.IntJNanomedicine.2012:72601–2611.21.LiposomalcurcumininhibitsLewislungcancergrowthprimarilythroughinhibitionofangiogenesis.OncologyLetters.2012,4:107-112.22.Anoveltruncatedbasicfibroblastgrowthfactorfragment-conjugatedpoly(ethyleneglycol)-cholesterolamphiphilicpolymericdrugdeliverysystemfortargetingtotheFGFR-overexpressingtumorcells.IntJPharmaceut.2011,408:173–182.23.ImprovedsolubilityandpharmacokineticsofPEGylatedliposomalhonokiolandhumanplasmaproteinbindingabilityofhonokiol.IntJPharmaceut.2011,410:169–174.24.TruncatedbFGF-mediatedcationicliposomalpaclitaxelfortumor-targeteddrugdelivery:Improvedpharmacokineticsandbiodistributionintumor-bearingmice.JPharmSci.2011,100:1196–1205.25.Preparation,Characterization,PharmacokineticsandBioactivityofHonokiol-in-Hydroxypropyl-β-Cyc-lodextrin-in-Liposome.JPharmSci.2011,100:3357–3364.26.Synthesis,structuralandinvitrostudiesofwell-dispersedmonomethoxypoly(ethyleneglycol)–honokiolconjugatemicelles.Biomedmater.2010,5:065006.27.Improvedtumor-targetingdrugdeliveryandtherapeuticefficacybycationicliposomemodifiedwithtruncatedbFGFpeptide.JournalofControlledRelease,2010,145(1):17-25.28.Schistosomajaponicum:efficientandrapidpurificationofthetetraspaninextracellularloop2,apotentialprotectiveantigenagainstschistosomiasisinmammalian.ExpParasitol.2010,126:456-461.

学术兼职

中国医药生物技术协会纳米生物技术分会委员，四川省药学会药物流行病学专委会委员，中国抗癌协会纳米肿瘤学专业委员会专业会员，中国抗癌协会肿瘤药物临床研究专业委员会专业会员，中国抗癌协会肿瘤精准治疗专业委员会专业会员，中国抗癌协会肿瘤分子医学专业委员会专业会员，免疫学会肿瘤免疫学分会会员,成都药学学会会员。